Crossref
BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors
European Journal of Cancer · 2026-11 · 248 · 117475
DOI: 10.1016/j.ejca.2026.117475 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von P. Li und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Li, P., Zhu, Y., Guo, Y., & Wang, S. (2026). BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors. European Journal of Cancer, 248, 117475. https://doi.org/10.1016/j.ejca.2026.117475
Vancouver
Li P, Zhu Y, Guo Y, Wang S. BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors. European Journal of Cancer. 2026;248:117475. doi:10.1016/j.ejca.2026.117475
BibTeX
@article{Li2026,
author = {Li, P. and Zhu, Y. and Guo, Y. and Wang, S.},
title = {BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117475},
doi = {10.1016/j.ejca.2026.117475}
}
EUVIMED